GHK-Cu Half-Life: How Long It Stays in Your System
Quick Answer
Bottom line first: GHK-Cu has a half-life of topical residence time varies. That's why it is dosed daily topical application typical.
GHK-Cu at a glance:
- Drug class: Cosmetic peptide
- Route: topical for most; injectable melanotans are unlicensed
- Typical frequency: daily topical application typical
- Half-life: topical residence time varies
GHK-Cu stays active in your system for a defined period after each dose. The half-life is topical residence time varies, and that single fact drives the dosing schedule, the missed-dose rules, and the washout timeline.
Half-Life Defined
The half-life is the time it takes for the concentration of a drug in the bloodstream to fall by half. It governs how often a drug needs to be dosed to maintain therapeutic levels and how long the drug persists after the last dose.
For GHK-Cu, the half-life is topical residence time varies. That number explains the daily topical application typical dosing schedule.
Time to Steady State
After starting (or changing) a dose, drug levels reach a new "steady state" after about 5 half-lives.
For GHK-Cu: practical steady state takes ~5x the half-life listed above. That's why dose changes don't show their full effect immediately.
How Long GHK-Cu Stays in Your System
A common question: "if I stop GHK-Cu, how long does it stay in my body?"
The standard rule of thumb is that a drug is essentially cleared after 5 half-lives. For GHK-Cu: that's approximately 5 times that interval. Effects on appetite, glucose, or other targets persist for a similar period before fully resolving.
For this compound, downstream effects depend on the cellular pathways involved.
Practical Implications
A long half-life:
- Allows less frequent dosing (better adherence)
- Smooths out peaks and troughs (often better tolerability)
- Means dose changes take longer to fully express
- Creates a longer "runway" if a dose is missed
A short half-life:
- Requires more frequent dosing
- Produces sharper concentration peaks (and matching side effects)
- Allows faster dose adjustments
- Provides faster clearance if stopped
GHK-Cu, with its short half-life, falls on the short end of this spectrum.
Half-Life and Missed Doses
If a dose is missed:
- Take the missed dose as soon as you remember if you're well within the dosing interval
- Skip it if you're closer to the next dose
- Never double up
The longer the half-life, the more forgiving the missed-dose window. For GHK-Cu, timing matters more.
Sponsored — Affiliate Disclosure
Ready to Start Your GLP-1 Journey?
Half-Life Across the Drug Class
Within the broader class of cosmetic peptide, half-lives vary significantly. Half-life variation across the class affects dosing frequency and tolerability profiles. See our comparison pages for direct comparisons.
Bottom Line
Half-life is one of the cleaner numbers in pharmacology. For GHK-Cu, the topical residence time varies figure is the one you reference whenever timing comes up.
Frequently Asked Questions
Frequently Asked Questions
Related Reading
- The Honest Guide to GHK-Cu: What Patients and Doctors Actually Say
- GHK-Cu Side Effects: 7 Things to Watch For (and How to Manage Them)
- GHK-Cu Outcomes Decoded: Who Responds Best and Why
- How Much Does GHK-Cu Really Cost? The Honest Breakdown
- Melanotan II Explained: How It Works and Who It's For
- Melanotan II Side Effects in 2026: Real Reports, Real Solutions
Sources
- Pickart L. The Human Tri-Peptide GHK and Tissue Remodeling. J Biomater Sci Polym Ed 2008;19:969.
- Habbema L et al. Risks of Unregulated Use of Alpha-Melanocyte-Stimulating Hormone Analogues. Br J Dermatol 2017;176:633.
This page is informational only and is not medical advice.
Related Articles
- →The Honest Guide to GHK-Cu: What Patients and Doctors Actually Say
- →GHK-Cu Side Effects: 7 Things to Watch For (and How to Manage Them)
- →GHK-Cu Outcomes Decoded: Who Responds Best and Why
- →How Much Does GHK-Cu Really Cost? The Honest Breakdown
- →Melanotan II Explained: How It Works and Who It's For
- →Melanotan II Side Effects in 2026: Real Reports, Real Solutions
